ASX:IIL - Investment thesis
- IIL’s lead drug candidate MIS416 will complete a double blinded placebo controlled Phase 2B trial for secondary progressive multiple sclerosis (SPMS) in April 2017
- There is already strong evidence of safety and likely efficacy from prior trials and a unique 7 year ‘compassionate use’ programme
- There are no drugs currently approved for the safe ongoing treatment of SPMS
- This unmet medical need could equate to a potential worldwide annual market of at least US$7.5B or more
- Many large drug companies are following IIL very closely
- IIL expects trial outcomes and a pharma transaction in H2/2017
To view Update please download PDF attached:
Download this document
